Patent · US Active

Use of M-CSF antibodies in the treatment of osteoarthritis or pain

US9243066B2 · kind B2 · utility

0Cited by

1References

4Claims

0Family size

Assignees

The University of Melbourne · AU
MORPHOSYS AG · DE

Inventors

Stefan Steidl · Munich, DE
John Allan Hamilton · Melbourne, AU
Andrew David Cook · Melbourne, AU

Key dates

Filing date	Jul 17, 2012
Grant date	Jan 26, 2016
Priority date	—
Expiry date	Aug 5, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.